Retatrutide is drawing interest as a potential weight-loss treatment, but its side effects remain under evaluation in clinical trials. Trial results can help show which health concerns deserve attention, but they cannot predict exactly how you will feel.
Retatrutide side effects are still being studied, so claims about safety need careful review. If you are weighing a medication for weight loss, you need facts about trial findings, not promises about results. This overview explains what researchers have reported and where the evidence still has limits.
Key Takeaways
- Digestive symptoms were common in Phase 3 trials.
- Reported rates differed across symptoms, doses, and trials.
- Trial results cannot tell you exactly how you will respond.
- As of November 7, 2026, Lilly describes retatrutide as investigational and not marketed.
- Discuss your health history and treatment choices with a clinician.
Treat claims about an investigational medication with caution until its safety and availability are established.
What Is Retatrutide, and Is It Available Yet?
Retatrutide is an investigational medication developed by Eli Lilly that activates three metabolic hormone receptors. A triple agonist is a medication that activates three receptor pathways, GLP-1, GIP, and glucagon.
The GLP-1 and GIP pathways influence appetite and digestion. Glucagon is another metabolic pathway, involved in how your body handles stored energy and sugar.
These pathways are why researchers study retatrutide for weight loss and other metabolic conditions. Its activity across GLP-1, GIP, and glucagon does not mean that every person will have the same effects.
As of October 2026, Eli Lilly described retatrutide as an investigational medicine being studied in Phase 3 trials. It had not been approved by the FDA or any other regulatory agency and was not available as a prescription medicine. Trial status and regulatory decisions can change, so check the latest official information before publication.
A planned or anticipated regulatory submission is not an approval, and a future filing date should not be treated as a guarantee that the medicine will become available. The FDA must review the relevant evidence and make an independent decision before a medicine can be marketed.
The FDA describes the Biologics License Application process for products regulated by its Center for Biologics Evaluation and Research. Filing an application is not the same as receiving approval.
That distinction matters if you see retatrutide offered outside a clinical trial. A product sold as retatrutide is not the same as an FDA-approved prescription medicine.
Trial participation follows a research protocol and medical oversight. It does not make the medication available for general use or show that it is right for you.
Until FDA approval, retatrutide is not an option you can obtain by ordinary prescription. Lilly warns that products sold online or outside legitimate clinical trials may contain unknown ingredients, contaminants, or incorrect amounts of active substance. Do not use products marketed as research-grade retatrutide.
FDA Warning About Unapproved Retatrutide Products
The FDA states that retatrutide is not a component of an FDA-approved drug and cannot be used in compounding under federal law. The agency has warned companies involved in marketing or distributing unapproved retatrutide. Do not buy or use products advertised as “research use only,” “research grade,” or compounded retatrutide. These products have not been reviewed by FDA for safety, effectiveness, or quality and may contain the wrong ingredient, an incorrect amount, or contaminants. Lilly also states that retatrutide remains investigational and is not available as a prescription medicine.
People who want to learn about research participation should use legitimate clinical-trial registries and contact trial investigators. Do not attempt to recreate a clinical-trial dose or use another person’s medication. For the current regulatory position, see the FDA warning on unapproved GLP-1 drugs and Lilly’s October 2026 retatrutide information.
What Are Retatrutide Side Effects in Clinical Trials?
Digestive symptoms were among the most frequently reported side effects in TRIUMPH-2, and the rates differed by symptom and dose. Diarrhea, nausea, constipation, and vomiting occurred more often in retatrutide groups than in the placebo group.
The table shows the share of participants who reported each gastrointestinal side effect during the 80-week trial. GI means gastrointestinal, or related to the stomach and intestines.
| Side effect | Placebo | 4 mg | 9 mg | 12 mg |
|---|---|---|---|---|
| Diarrhea | 13.2% | 27.4% | 33.5% | 33.6% |
| Nausea | 8.0% | 13.7% | 20.8% | 28.0% |
| Constipation | 9.4% | 14.0% | 16.2% | 16.8% |
| Vomiting | 4.2% | 5.5% | 10.2% | 15.7% |
For example, nausea was reported by 28.0% of participants taking 12 mg, compared with 8.0% taking placebo. Those percentages describe groups of trial participants, not your personal chance of having nausea.
Placebo participants received a treatment without retatrutide. Their reported symptoms provide useful context, but the placebo rate does not prove that a symptom in the medication group came from treatment.
The different rates also show why one symptom should not stand in for all retatrutide side effects. Diarrhea was reported more often than vomiting in each dose group, while nausea rates rose across the listed doses.
These trial findings can help you understand the kinds of symptoms researchers tracked. They do not show how severe a symptom will be for one person or how long it may last.
Clinical trial data also reflect the people and conditions in that study. A different trial may report different rates, even when it studies the same medication.
These percentages describe an 80-week trial, not a guarantee of what you will experience.
How Did Side Effects Differ in Another Phase 3 Trial?
TRIUMPH-3 also found frequent digestive symptoms, though its percentages are not identical to TRIUMPH-2. Its 80-week results show that reported rates can differ across trials and participant groups.
The table lists the reported GI symptoms in TRIUMPH-3. The trial included placebo, 9 mg, and 12 mg groups.
| Side effect | Placebo | 9 mg | 12 mg |
|---|---|---|---|
| Diarrhea | 8.7% | 30.1% | 24.4% |
| Nausea | 5.8% | 21.7% | 22.4% |
| Constipation | 7.1% | 18.0% | 15.7% |
| Vomiting | 2.6% | 9.8% | 10.2% |
Adverse events led to treatment discontinuation in 9.8% of the 9 mg group and 13.5% of the 12 mg group. The placebo discontinuation rate was 4.8%.
Those rates do not establish a simple dose pattern across trials. In TRIUMPH-3, some GI rates were higher at 9 mg, while others were slightly higher at 12 mg.
Trial data can be affected by who enrolled, how the trial ran, and how participants received treatment. A rate in one study cannot be treated as a direct prediction for another group.
It would also be misleading to combine the two trials into one side-effect rate. Each study had its own participants, treatment groups, and design.
Read each trial’s results in the context of its own participants and design.
What Are Dysesthesia and Reduced Appetite?
Reduced appetite and altered skin sensation are different experiences, but both appeared in the TRIUMPH-2 safety results. Decreased appetite was reported more often at higher doses, while dysesthesia was uncommon in each group.
These findings add to the range of retatrutide side effects reported in clinical trials. They may affect daily routines in ways that a percentage alone cannot describe.
Reduced appetite and eating enough
Reduced appetite is part of the medication’s intended effect, but it can also make it harder to eat and drink enough. Decreased appetite occurred in 4.5% of placebo participants, 5.8% at 4 mg, 12.3% at 9 mg, and 17.1% at 12 mg.
A lower appetite may change how often you want meals or how much you can eat at once. During weight loss, regular food and fluid intake still matter for your health and daily function.
If appetite changes make it hard to meet basic needs, tell your clinician. They can assess the change alongside your symptoms, body weight, and overall health.
Dysesthesia and altered skin sensation
Dysesthesia means an altered or unpleasant skin sensation, such as tingling or burning. In TRIUMPH-2, it occurred in 0.7% of placebo participants, 4.5% at 4 mg, 5.6% at 9 mg, and 7.3% at 12 mg.
People may describe dysesthesia as pins and needles, burning, or unusual sensitivity to touch. The trial percentages show that reports were less common than digestive symptoms, but the sensation can still disrupt daily life.
Persistent symptoms can have different causes, so a clinician can help assess them. Describe where the feeling occurs, when it started, and whether it changes over time.
Persistent tingling, burning, or sensitivity that affects daily life deserves a conversation with a clinician.
What Should You Know About Retatrutide and Heart Health?
Retatrutide trials have recorded a rise in resting heart rate, while cardiovascular event results need cautious interpretation. At 12 mg, resting heart rate rose by an average of about 6.7 beats per minute.
The reported change peaked around week 24, then declined toward baseline by weeks 36-48. Irregular heartbeats were reported in 2-11% of retatrutide participants, compared with about 2% with placebo.
Resting heart rate and rhythm
A change in average heart rate does not show what your own heart rate will do. The trial range for irregular heartbeats also does not prove that treatment caused every reported event.
Palpitations can feel like a flutter, skipped beat, or pounding heartbeat. A clinician should assess palpitations or a racing heart that stays elevated.
What MACE trial results mean
MACE-3 means cardiovascular death, heart attack, or stroke. MACE-5 includes those events, plus all-cause death, a heart failure event, and coronary revascularization, a procedure to restore blood flow to the heart.
In TRIUMPH-3, researchers recorded 27 MACE-3 events among participants assigned retatrutide and 23 among those assigned placebo. The MACE-3 hazard ratio was 1.12, with a 95.0% confidence interval of 0.64 to 1.96.
The MACE-5 hazard ratio was 0.82, with a 95.0% confidence interval of 0.55 to 1.22. A hazard ratio compares event rates over time between groups, while its confidence interval shows uncertainty around that estimate.
Both confidence intervals include 1.0, so these results do not establish a clear cardiovascular benefit or harm. The event counts and hazard ratios are not proof that retatrutide prevents or causes cardiovascular events.
Seek prompt medical assessment for chest discomfort, fainting, or a sustained racing heartbeat.
Which Less Common or Serious Risks Need Medical Attention?
Serious events were uncommon in the Phase 2 trial, but uncommon does not mean impossible. One case of pancreatitis was reported at 12 mg, and gallbladder events occurred in about 1.1% of retatrutide participants.
No gallbladder events were reported in the placebo group. A reported event during a trial does not, by itself, prove that the medication caused it.

Pancreatitis and gallbladder problems
Pancreatitis is inflammation of the pancreas. Severe, persistent abdominal pain needs urgent evaluation, especially if it comes with vomiting or feels different from a brief stomach upset.
Gallbladder problems can occur during weight loss for reasons beyond a particular medication. Rapid weight loss can also contribute to gallstone risk, so a new symptom needs assessment rather than a guess about its cause.
Discuss these concerns with a clinician if any apply to you:
- Past pancreatitis
- Gallbladder disease
- Persistent severe abdominal pain
Other reported events
In a Phase 2 obesity trial, serious adverse events occurred in 4% of both retatrutide and placebo participants. This equal rate does not show that every event had the same cause or type.
Urinary tract infections were reported in TRIUMPH-2 in 6.6% of placebo participants, 3.8% at 4 mg, 6.3% at 9 mg, and 8.0% at 12 mg. The rates varied across groups, so the reports alone cannot show that treatment caused an infection.
Tell a clinician about a history of pancreatitis or gallbladder disease before considering any weight-management medication.
Which Symptoms Should Prompt Urgent Care?
Trouble breathing, severe abdominal pain, or vomiting that prevents you from drinking calls for action rather than watchful waiting. Call 911 for difficulty breathing or swelling of your face or throat.
A suspected severe allergic reaction needs emergency care. Severe or persistent symptoms should not be self-diagnosed, since several health problems can feel alike.
Use these signs to decide when to seek help:
- Trouble breathing or swelling of the face or throat
- Severe, persistent abdominal pain
- Ongoing vomiting or inability to keep fluids down
- Racing heartbeat with fainting or chest discomfort
If vomiting continues beyond 24 hours, contact a clinician. Do the same sooner if you cannot keep fluids down, since dehydration can become a concern.
For a racing heartbeat, fainting, or chest discomfort, get prompt medical assessment. If you feel faint or have chest discomfort, do not wait to see whether the symptom passes.
Not every side effect needs emergency care, but a symptom that worsens quickly needs a timely response. Tell the medical team what you took and when symptoms began, if you know.
If symptoms feel severe or rapidly worsen, seek urgent medical care instead of waiting for the next appointment.
Can Dose Changes Help Limit Side Effects?
Dose escalation is a key part of tolerability, but retatrutide should not be self-dosed outside a clinical trial. Slower increases can give your body more time to adjust to treatment.
Trial findings can explain why researchers test gradual escalation. They are not a personal dose plan for you to follow.

Why gradual escalation matters
In Phase 2 data, starting at 2 mg rather than 4 mg reduced nausea. Direct assignment to 8 mg without titration nearly doubled GI symptom rates compared with gradual escalation.
These findings suggest that the pace of dose increases can affect how well people tolerate treatment. They do not establish the right dose or schedule for a particular person.
Higher doses were not linked to a simple, steady pattern in every outcome. A trial schedule also reflects close monitoring that may not match care outside research.
What to do when symptoms persist
In TRIUMPH-2, adverse events led to treatment discontinuation in 4.9% of placebo participants, 3.8% at 4 mg, 11.6% at 9 mg, and 7.7% at 12 mg. These results show that some participants stopped treatment, with rates that differed by group.
Only a qualified clinician or the responsible trial team can guide dose decisions. If symptoms persist, you can raise three practical points:
- Report symptoms that continue or interfere with daily life.
- Ask whether dose escalation should pause.
- Keep a record of symptoms and when they occur.
A simple log can note meals, symptoms, and timing without trying to diagnose the cause. Share it with the clinician guiding your care or trial treatment.
Do not increase, decrease, or restart an investigational medication without guidance from the responsible clinical team.
Do Side Effects Differ for Women and Men?
The main trial side effects are not established as different for women and men, but personal circumstances can change the safety discussion. Available information does not establish separate retatrutide side-effect lists by sex.
Your health history, reproductive plans, and other medicines still matter. These details can shape what a clinician needs to consider before any treatment.
Pregnancy, contraception, and women’s health
Pregnancy, trying to conceive, breastfeeding, and contraception deserve a clinician discussion. Retatrutide remains investigational, and its safety in these situations is not established.
Do not assume that trial findings apply to pregnancy or breastfeeding. Share your plans and current birth control use during a treatment discussion.
Men’s health and individual risk
Available information does not establish a different side-effect profile for men. Your personal health history and other medicines can still affect the safety discussion.
A clinician can review health conditions and medications that matter for your care. The same review helps place trial findings in the context of your own needs.
Hair shedding during weight loss
Rapid weight loss can trigger temporary hair shedding called telogen effluvium. It often becomes noticeable about 2-3 months after the trigger.
Hair shedding is not proof of a direct medication effect. A clinician can assess other possible causes, including changes in health or nutrition.
Raise these topics with a clinician:
- Reproductive plans
- Current medicines
- Sudden or persistent hair shedding
Discuss pregnancy plans, breastfeeding, or persistent hair loss with a qualified clinician rather than relying on a general rule.
Does Retatrutide Raise Cancer or Thyroid Concerns?
The thyroid concern discussed for GLP-1 medicines comes from animal findings, not a confirmed retatrutide cancer risk in people. Rodent studies of GLP-1 receptor agonists found thyroid C-cell tumors, but that does not prove human harm.
Thyroid C cells make hormones that help regulate the body. The animal finding led to a precaution for GLP-1 receptor agonists, a medicine class related to one of retatrutide’s pathways.

A rodent finding is not the same as a confirmed cancer signal in people taking retatrutide. It also cannot settle what risk, if any, may apply to an individual.
Medullary thyroid carcinoma is a rare thyroid cancer that begins in C cells. Multiple endocrine neoplasia type 2, or MEN2, is an inherited condition linked to certain tumors.
If you or a close family member has had medullary thyroid carcinoma or MEN2, tell your clinician. That history is important in a discussion about GLP-1 medicines and investigational treatments.
Do not treat a class precaution as proof that retatrutide causes cancer. The evidence described in the precaution comes from rodents, not a confirmed human retatrutide cancer risk.
Your clinician can consider your family history alongside other health factors. A personal risk discussion is more useful than drawing conclusions from animal findings alone.
Share any personal or family history of medullary thyroid carcinoma or MEN2 with your clinician.
What Is Known About Long-Term Effects and Stopping?
Retatrutide’s long-term safety profile is still being established, so evidence from other medications needs careful labeling. Long-term safety and real-world experience remain under study because retatrutide is investigational.
Trials can track side effects over their study periods, but they cannot answer every question about many years of use. Results also depend on who joined the trial and how long researchers followed them.
What trial follow-up can show
Long-term follow-up can show which events participants report while they take part in a study. It may also track changes over time, but it cannot guarantee what will happen after treatment ends.
As study periods grow, researchers can learn more about ongoing effects and risks. Retatrutide’s safety record will continue to depend on further research and review.
What weight regain evidence can and cannot tell you
A tirzepatide study called SURMOUNT-4 offers an example of weight changes after treatment, not retatrutide withdrawal data. Participants lost 20.9% of their starting weight over 36 weeks on tirzepatide.
After switching to placebo, they regained 14% of their starting weight during the following year. That result describes participants who stopped tirzepatide, not people who stopped retatrutide.
The drugs are different, so the result cannot predict exactly what will happen to your weight after stopping retatrutide. Changes may differ from person to person and across treatments.
If treatment changes, a clinician can help plan ongoing weight management. That plan can address follow-up and other care suited to your health needs.
If treatment changes, make a follow-up plan with a clinician rather than assuming results from another medication will apply to you.
What Can You Use While Retatrutide Is Investigational?
If you are considering medication now, semaglutide and tirzepatide have FDA-approved weight-management products, while retatrutide remains investigational. Wegovy and Zepbound are approved U.S. options for weight management.
The medicines act on different hormone pathways. The table shows their targets and U.S. status.
| Medication | Receptor targets | U.S. status |
|---|---|---|
| Retatrutide | GLP-1, GIP, glucagon | Investigational |
| Semaglutide (Wegovy) | GLP-1 | FDA-approved for weight management |
| Tirzepatide (Zepbound) | GLP-1, GIP | FDA-approved for weight management |
Ozempic is a semaglutide brand used for type 2 diabetes, while Wegovy is the weight-management brand. A brand name and its approved use are not interchangeable.
No head-to-head trials establish retatrutide as better than semaglutide or tirzepatide. Results from separate trials cannot prove that one medication works best for every person.
Retatrutide has no official U.S. price before FDA approval. Any future cost would depend on approval, insurance coverage, and available savings programs.
Ask a licensed clinician which currently approved option, if any, fits your health history and goals.
Conclusion
Retatrutide’s trial results are promising, but its safety and availability are not settled. Trial findings cannot predict your personal response, and the medication remains investigational.
If you are considering weight loss treatment, a licensed clinician can help you compare approved options with your health needs. Your other medicines and health history matter as much as trial averages.
Use health information as a starting point, not a replacement for personal care. Review the site’s health information disclaimer and discuss decisions with a qualified professional.
Bring your health history, current medicines, and treatment goals to a clinician before making a weight-management decision.
FAQ
What happens when you stop taking retatrutide?
Retatrutide-specific stopping data are limited, so weight or symptom changes after stopping cannot be predicted with confidence. In SURMOUNT-4, participants who took tirzepatide lost 20.9% of their starting weight over 36 weeks, then regained 14% during the next year after switching to placebo. That was a tirzepatide result, not retatrutide evidence. Ask a clinician to plan any treatment change.
What to expect when taking retatrutide?
In trials, common GI symptoms included nausea, diarrhea, constipation, and vomiting. These symptoms often occurred during dose increases, though your own response may differ from the group results. Some participants had more than one symptom, and trial rates cannot tell you how severe symptoms might feel. Retatrutide remains investigational, so it is not for routine prescription or unsupervised use.
What are the benefits of retatrutide?
Retatrutide is being studied for weight loss and metabolic conditions through activity at GLP-1, GIP, and glucagon receptors. This triple agonist action is intended to affect appetite and other metabolic processes. Researchers are studying its potential, but a trial result does not establish a benefit for every person. Retatrutide is not an approved treatment, so it is not an option for ordinary prescription use.
Will retatrutide burn belly fat?
No medication can selectively direct weight loss to belly fat. As body weight changes, fat loss can occur in different areas, and fat distribution varies between people. Retatrutide is being studied for weight loss, not for targeting one body region. Its investigational status also means you should not use products sold as retatrutide outside a supervised clinical trial.
Is retatrutide better than Ozempic?
No head-to-head trials establish that retatrutide is better than Ozempic. Retatrutide remains investigational, while semaglutide is an established FDA-approved medicine with different brand indications. Ozempic is used for type 2 diabetes, while Wegovy is the semaglutide brand approved for weight management. Separate trial results cannot fairly rank the medicines for every person or health goal.
How fast does retatrutide kick in?
Some trial participants may begin losing weight within about 4-8 weeks, but timing varies from person to person. Early changes do not show how much weight someone will lose over a full study period. Retatrutide is not approved for routine use, and trial schedules involve study oversight. Do not use early weight changes to adjust or seek an investigational dose on your own.
What is the strongest weight loss injection?
There is no reliable way to rank weight-loss injections by comparing results from separate trials alone. Studies may include different participants, treatment periods, and methods. The right choice depends on evidence for an approved option, your health history, and your treatment goals. A licensed clinician can review these factors and explain which available treatment may fit your needs.
Why am I not losing weight on retatrutide?
Weight changes vary, and retatrutide is investigational rather than a routine prescription treatment. A clinician can assess other medicines, health factors, and expectations that may affect your weight. Trial results do not guarantee an individual response, even when a participant follows a study plan. Do not change a dose or seek an unapproved product on your own; discuss your concerns with qualified care providers.
Related Reading
Authoritative Sources
- ClinicalTrials.gov: TRIUMPH-2 (NCT05929079)
- Eli Lilly: What to know about investigational retatrutide (updated October 2026)
Retatrutide Safety: Do Not Use Products Sold Outside Clinical Trials
Regulatory status: As of November 7, 2026, Eli Lilly describes retatrutide as an investigational medicine in Phase 3 clinical trials, not an FDA-approved or commercially available prescription drug. Trial results do not make it available for routine treatment. A website or seller offering retatrutide for personal use is not evidence that the product is legitimate, quality-controlled or safe.
Unapproved products: Do not inject or ingest products labelled “research use only,” “research grade,” or compounded retatrutide. Their identity, strength, sterility and contaminants may be uncertain. Do not attempt to copy trial doses, change a dose yourself, or combine retatrutide with another GLP-1 medicine. People interested in research should use a legitimate clinical-trial registry and contact the trial team.
How to interpret trial adverse events: Percentages in a trial describe the participants and doses studied; they are not an individual’s personal risk estimate and may not predict long-term safety. Retatrutide’s safety profile is still being evaluated. Do not treat a side-effect list as a complete prescribing label or as evidence that the drug is suitable for weight loss outside a supervised study.
Sources: Eli Lilly: What to know about retatrutide (updated October 2026); FDA: Concerns with unapproved GLP-1 drugs used for weight loss.
